Navigation Links
BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:4/21/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the final scheduled review by the DSMB prior to the completion of MAESTRO-01. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. Results from MAESTRO-01 are expected in the second half of this year.

    About MAESTRO-01
    ----------------

MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with secondary progressive MS. The study is being conducted at 47 sites across Canada and nine countries in Europe and includes 611 patients being administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease, as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive). Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multip
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
2. BioMS Medical Announces 2008 Year End Results
3. BioMS Medical warrant extension
4. BioMS Medical to present at BIO CEO and Investor Conference
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. BioMS Medical recognized at Scrip Awards 2008
7. BioMS Medical Announces Third Quarter 2008 Results
8. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Washington, PA (PRWEB) March 02, 2015 ... and ReachMD announced today the launch of ... designed to educate healthcare professionals on the application of ... , The series features peer-to-peer interviews conducted during the ... ,     Translational Genomics and Health Outcomes Research: ...
(Date:3/2/2015)... York, NY (PRWEB) March 02, 2015 ... Testing Services industry has experienced robust growth. The ... consumer products, industrial materials, energy resources and other goods, ... and rising government regulation. As a result, IBISWorld forecasts ... of 2.8% to reach $946.8 million over the five-year ...
(Date:3/2/2015)... 2015 Analyzing a puzzling multisystem disorder ... new syndrome, shedding light on key biological processes ... information to help caregivers manage the disorder, and ... "This syndrome illuminates a very important pathway ... that controls many other genes," said study leader ...
(Date:3/2/2015)... British Columbia , March 2, 2015 /PRNewswire/ ... a clinical stage biopharmaceutical company specializing in the ... Craig Schneider , Chief Executive Officer, will ... at VirtualInvestorConferences.com. DATE: Thursday, March 5, ... click the red "register/ watch event now" button ...
Breaking Biology Technology:American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4InMed Pharmaceuticals to Present Investor Webcast March 5 2
... Arpida Ltd.,(SWX: ARPN) announces today that it ... Food and Drug Administration (FDA) regarding its New ... of complicated,skin and skin structure infections (cSSSI). The ... the application for iclaprim in its current form ...
... six genome centres demonstrated the power of partnerships ... at the International Plant and Animal Genomics Conference ... researchers, funders and other international stakeholders enjoyed Canadian ... event. , "This Canadian reception was a truly ...
... Fla. --- Algae is a livid green giveaway of nutrient ... action in tiny particles that would turn different colors if ... health in the blood. , Now, University of Florida engineering ... a major hurdle to creating such "smart dust.",The feat, which ...
Cached Biology Technology:FDA Issues Complete Response Letter for Iclaprim 2Researchers: Molecular forklifts overcome obstacle to 'smart dust' 2Researchers: Molecular forklifts overcome obstacle to 'smart dust' 3
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
(Date:1/22/2015)... the leading source of biometrics industry news, interviews and thought ... "When we launched FindBiometrics 12 years ago the industry ... and CEO of FindBiometrics. "Now it,s maturing very quickly. More ... on a very broad scale.  We are known for providing ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... (August 27, 2010) Although having a high body ... cardiovascular disease, researchers are only beginning to understand how ... of the disease. Now, a study of a subset ... (KEEPS), suggests that as BMI increases, so do platelet ...
... cell-to-cell signaling pathway that designates the future location of ... succeeded in activating this signal more widely across the ... sensory structures began growing in spots where they don,t ... called hair cells, which respond to sound waves and ...
... is available in German . , Plants have ... fend off herbivores by producing toxins, but also do so ... perceived by predatory insects; these predators are lured to the ... thereby providing a benefit for the plant. Since ...
Cached Biology News:Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3Tuning into cell signals that tell where sensory organs will form inside the ear 2Tuning into cell signals that tell where sensory organs will form inside the ear 3Lethal backfire: Green odor with fatal consequences for voracious caterpillars 2Lethal backfire: Green odor with fatal consequences for voracious caterpillars 3
Special grade: for electrophoresis...
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
... cytochrome P450 (CYP450) metabolite postulated to play ... cerebral vasculature. In rat cerebral microvessels, 20-HETE ... vasoconstriction. 20-HETE is excreted mainly as the ... (20-40 pg/ml in human urine) is about ...
... enables you to insert a transposable element ... by in vitro transposition. It uses TnsABC* ... the DNA target. Target DNA may be ... depending on your interests (6-8). If the ...
Biology Products: